Skip to content

Depreciation at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Medline, Inc.
 logo
Medline, Inc. MDLN
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
SS&C Technologies logo
SS&C TechnologiesSSNC
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Segments

By segment

See full
Reportable Segment$6.75M+0.9%

Other financials

Income statement

See full
Revenue$706.6M+26.5%
Operating income$141.5M+24.6%
Net income$123.9M+8.1%
EPS (diluted)$4.28+16.6%

Balance sheet

See full
Cash & equivalents$652.7M+47.9%
Total debt$146.1M-2.8%
Total equity$598.3M+0.8%
Total assets$2.1B+12.2%

Cash flow

See full
Operating cash flow$151.8M+20.6%
CapEx$6.8M-31.8%
Free cash flow$145.0M+25.1%

Valuation

See full
Market cap$13.14B+46.8%
Enterprise value$12.64B+45.9%
P/E28.6×+7.0×
P/S4.9×+0.8×

Profitability

See full
Operating margin21%-0.1pp
Net margin17.2%-2.1pp
FCF margin26.5%+1.5pp

Returns & leverage

See full
Return on equity77.3%+11.4pp
Debt / equity0.2×0.0×
Current ratio0.8×+0.1×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medpace Holdings, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Medpace Holdings, Inc.'s depreciation?
Medpace Holdings, Inc. (MEDP) reported depreciation of $6.75M in Q1 2026.
How has Medpace Holdings, Inc.'s depreciation changed year-over-year?
Medpace Holdings, Inc.'s depreciation increased by 0.9% year-over-year, from $6.69M to $6.75M.
What is the long-term trend for Medpace Holdings, Inc.'s depreciation?
Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s depreciation has grown at a 14.2% compound annual growth rate (CAGR), from $16.01M to $27.18M.